Shinobi Therapeutics, an FTI portfolio company pioneering cell therapies for autoimmune diseases and oncology, has appointed Luis Borges, PhD, as Chief Scientific Officer and Steven Katz, MD, as Chief Medical Officer.
Luis Borges, PhD, a leader in immunology and oncology, brings extensive experience advancing therapies from discovery to clinical development. Steven Katz, MD, a clinical development expert, will drive Shinobi’s pipeline into the clinic. These appointments come as Shinobi accelerates the development of its iPSC-T and NK cell products, targeting GPC3+ solid tumors, and autoimmune disease, respectively.
The addition of these key leaders underscores Shinobi’s focus on building a strong foundation for clinical development and advancing its innovative cell therapies to address significant unmet needs.
For more information, visit Shinobi Therapeutics.
Read the full ENDPOINTS article here.
